[2]
Bellmann R, Smuszkiewicz P. Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients. Infection. 2017 Dec:45(6):737-779. doi: 10.1007/s15010-017-1042-z. Epub 2017 Jul 12
[PubMed PMID: 28702763]
[3]
Fisher JF, Sobel JD, Kauffman CA, Newman CA. Candida urinary tract infections--treatment. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2011 May:52 Suppl 6():S457-66. doi: 10.1093/cid/cir112. Epub
[PubMed PMID: 21498839]
[4]
Day JN, Chau TTH, Wolbers M, Mai PP, Dung NT, Mai NH, Phu NH, Nghia HD, Phong ND, Thai CQ, Thai LH, Chuong LV, Sinh DX, Duong VA, Hoang TN, Diep PT, Campbell JI, Sieu TPM, Baker SG, Chau NVV, Hien TT, Lalloo DG, Farrar JJ. Combination antifungal therapy for cryptococcal meningitis. The New England journal of medicine. 2013 Apr 4:368(14):1291-1302. doi: 10.1056/NEJMoa1110404. Epub
[PubMed PMID: 23550668]
[5]
Spec A, Powderly WG. Cryptococcal meningitis in AIDS. Handbook of clinical neurology. 2018:152():139-150. doi: 10.1016/B978-0-444-63849-6.00011-6. Epub
[PubMed PMID: 29604972]
[6]
Houšť J, Spížek J, Havlíček V. Antifungal Drugs. Metabolites. 2020 Mar 12:10(3):. doi: 10.3390/metabo10030106. Epub 2020 Mar 12
[PubMed PMID: 32178468]
[7]
Antonello VS, Appel da Silva MC, Cambruzzi E, Kliemann DA, Santos BR, Queiroz-Telles F. Treatment of severe chromoblastomycosis with itraconazole and 5-flucytosine association. Revista do Instituto de Medicina Tropical de Sao Paulo. 2010 Nov-Dec:52(6):329-31
[PubMed PMID: 21225217]
[8]
Edlind TD, Katiyar SK. Mutational analysis of flucytosine resistance in Candida glabrata. Antimicrobial agents and chemotherapy. 2010 Nov:54(11):4733-8. doi: 10.1128/AAC.00605-10. Epub 2010 Sep 7
[PubMed PMID: 20823283]
[9]
Kunka ME, Cady EA, Woo HC, Thompson Bastin ML. Flucytosine Pharmacokinetics in a Critically Ill Patient Receiving Continuous Renal Replacement Therapy. Case reports in critical care. 2015:2015():927496. doi: 10.1155/2015/927496. Epub 2015 Jul 12
[PubMed PMID: 26246919]
Level 3 (low-level) evidence
[10]
Sakkas A, Zarogoulidis P, Domvri K, Hohenforst-Schmidt W, Bougiouklis D, Kakolyris S, Zarampoukas T, Kioumis I, Pitsiou G, Huang H, Li Q, Meditskou S, Tsiouda T, Pezirkianidis N, Zarogoulidis K. Safety and efficacy of suicide gene therapy with adenosine deaminase 5-fluorocytosine silmutaneously in in vitro cultures of melanoma and retinal cell lines. Journal of Cancer. 2014:5(5):368-81. doi: 10.7150/jca.9147. Epub 2014 Apr 17
[PubMed PMID: 24799955]
[11]
Kyriakidis I, Tragiannidis A, Munchen S, Groll AH. Clinical hepatotoxicity associated with antifungal agents. Expert opinion on drug safety. 2017 Feb:16(2):149-165. doi: 10.1080/14740338.2017.1270264. Epub 2016 Dec 16
[PubMed PMID: 27927037]
Level 3 (low-level) evidence
[12]
Folk A, Balta C, Herman H, Ivan A, Boldura OM, Paiusan L, Ardelean A, Hermenean A. Flucytosine and Amphotericin B Coadministration Induces Dose-Related Renal Injury. Dose-response : a publication of International Hormesis Society. 2017 Apr-Jun:15(2):1559325817703461. doi: 10.1177/1559325817703461. Epub 2017 Jun 5
[PubMed PMID: 28620270]
[13]
Sohail MA, Ikram U. Flucytosine-induced colitis. BMJ case reports. 2014 Apr 28:2014():. doi: 10.1136/bcr-2013-203381. Epub 2014 Apr 28
[PubMed PMID: 24777084]
Level 3 (low-level) evidence
[14]
Pilmis B, Jullien V, Sobel J, Lecuit M, Lortholary O, Charlier C. Antifungal drugs during pregnancy: an updated review. The Journal of antimicrobial chemotherapy. 2015 Jan:70(1):14-22. doi: 10.1093/jac/dku355. Epub 2014 Sep 8
[PubMed PMID: 25204341]
[15]
Srichatrapimuk S, Sungkanuparph S. Integrated therapy for HIV and cryptococcosis. AIDS research and therapy. 2016 Nov 29:13(1):42
[PubMed PMID: 27906037]